Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) <i>EGFR</i> Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study

Xiong, Liwen; Li, Rong; Sun, Jiayuan; Lou, Yu‐Qing; Zhang, Weiyan; Bai, Hao; Wang, Huiming; Shen, Jie; Jing, Bo; Shi, Chunlei; Zhong, Hua; Gu, Aiqin; Jiang, Liyan; Shi, Jian-Xing; Fang, Wentao; Zhao, Heng; Zhang, Jie; Wang, Junyuan; Ye, Junyi; Han, Baohui

doi:10.1634/theoncologist.2018-0120

Cited by 82 publications

(76 citation statements)

References 17 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further confirm the role of the LDHAP5 pseudogene at the in vivo and in vitro level, we need to construct ovarian cancer cell lines that differentially express LDHAP5, with clinical pathological specimens from ovarian cancer patients also used to verify our findings. EGFR antagonists (e.g., gefitinib, lapatinib, erlotinib) have been used in a variety of cancers, including pancreatic, small cell lung, and colorectal cancer [42][43][44]. Once our research is successfully validated, it may be used in ovarian cancer in the future.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma

et al. 2020

View full text Add to dashboard Cite

Background: We aimed to identify differentially expressed pseudogenes and explore their potential functions in four types of common gynecological malignancies (e.g., cervical squamous cell carcinoma, ovarian serous cystadenocarcinoma, uterine corpus endometrial carcinoma, and uterine carcinosarcoma) using bioinformatics technology. Materials and methods: We identified up-regulated and down-regulated pseudogenes and built a pseudogene-miRNA-mRNA regulatory network through public datasets to explore their potential functions in carcinogenesis and cancer prognosis. Results: Among the 63 up-regulated pseudogenes identified, LDHAP5 demonstrated the greatest potential as a candidate pseudogene due to its significant association with poor overall survival in ovarian serous cystadenocarcinoma. KEGG pathway analysis revealed that LDHAP5 showed significant enrichment in MicroRNAs in cancer, Pathway in cancer and PI3K-AKT signaling pathway. Further analysis revealed that EGFR was the potential target mRNA of LDHAP5, which may play an important role in ovarian serous cystadenocarcinoma. Conclusions: LDHAP5 was associated with the occurrence and prognosis of ovarian serous cystadenocarcinoma, and thus shows potential as a novel therapeutic target against such cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…EGFR antagonists (e.g., ge tinib, lapatinib, erlotinib) have been used in a variety of cancers, including pancreatic, small cell lung, and colorectal cancer. (42)(43)(44) Once our research is successfully validated, it may be used in ovarian cancer in the future. With continuing research, more pseudogene functions and corresponding mechanisms will be revealed, which could help in the identi cation of novel biomarkers, development of speci c drug design, and the adoption of personalized treatment in the future.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma

Lin

Meng

Cao

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: We aimed to identify differentially expressed pseudogenes and explore their potential functions in four types of common gynecological malignancies (e.g., cervical squamous cell carcinoma, ovarian serous cystadenocarcinoma, uterine corpus endometrial carcinoma, and uterine carcinosarcoma) using bioinformatics technology. Materials & methods: We identified up-regulated and down-regulated pseudogenes and built a pseudogene-miRNA-mRNA regulatory network through public datasets to explore their potential functions in carcinogenesis and cancer prognosis. Results: Among the 63 up-regulated pseudogenes identified, LDHAP5 demonstrated the greatest potential as a candidate pseudogene due to its significant association with poor overall survival in ovarian serous cystadenocarcinoma. KEGG pathway analysis revealed that LDHAP5 showed significant enrichment in MicroRNAs in cancer, Pathway in cancer and PI3K-AKT signaling pathway. Further analysis revealed that EGFR was the potential target mRNA of LDHAP5, which may play an important role in ovarian serous cystadenocarcinoma. Conclusions: LDHAP5 was associated with the occurrence and prognosis of ovarian serous cystadenocarcinoma, and thus shows potential as a novel therapeutic target against such cancer.

show abstract

“…The second was a single-arm trial and reported a 42% response rate, with 21% downstaging to T0-3 N0 M0. On a pathological level, 50% of patients had a partial response, while 50% had stable disease [ 26 ]. The third study compared neoadjuvant erlotinib among 15 patients whose tumors had EGFR mutations to chemotherapy in 16 patients without these alterations [ 27 ].…”

Section: Epidermal Growth Factor Receptor (Egfr) Mutationsmentioning

confidence: 99%

“…To name a few, BRAF V600E mutations are successfully targeted by combined BRAF/MEK inhibitors, mainly dabrafenib and trametinib, with high response rates and relatively low toxicity [ 33 ]. Similarly, ROS1 rearrangements can be targeted with drugs, including crizotinib, ceritinib, lorlatinib, entrectinib, or repotrectinib [ 26 ]. MET alterations, including exon 14 mutations and amplifications, can be treated with a variety of TKIs, among the most common, crizotinib, capmatinib, and tepotinib [ 34 , 35 , 36 , 37 ].…”

Section: Others Oncogenic Driversmentioning

confidence: 99%

Targeted Therapies in Early Stage NSCLC: Hype or Hope?

Friedlaender

Addeo

Russo

et al. 2020

IJMS

View full text Add to dashboard Cite

Non-small-cell lung cancer (NSCLC) represents roughly 85% of lung cancers, with an incidence that increases yearly across the world. The introduction in clinical practice of several new and more effective molecules has led to a consistent improvement in survival and quality of life in locally advanced and metastatic NSCLC. In particular, oncogenic drivers have indeed transformed the therapeutic algorithm for NSCLC. Nearly 25% of patients are diagnosed in an early stage when NSCLC is still amenable to radical surgery. In spite of this, five-year survival rates for fully resected early stage remains rather disappointing. Adjuvant chemotherapy has shown a modest survival benefit depending on the stage, but more than half of patients relapse. Given this need for improvement, over the last years different targeted therapies have been evaluated in early-stage NSCLC with no survival benefit in unselected patients. However, the identification of reliable predictive biomarkers to these agents in the metastatic setting, the design of molecularly-oriented studies, and the availability of novel potent and less toxic agents opened the way for a novel era in early stage NSCLC treatment. In this review, we will discuss the current landscape of targeted therapeutic options in early NSCLC.

show abstract

Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study

Abstract: Neoadjuvant erlotinib was well tolerated and may improve the radical resection rate in this patient population. Next-generation sequencing may predict outcomes with preoperative TKIs.

Cited by 82 publications

References 17 publications

Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma

Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma

Comprehensive analysis of LDHAP5 pseudogene expression and potential pathogenesis in ovarian serous cystadenocarcinoma

Targeted Therapies in Early Stage NSCLC: Hype or Hope?

Contact Info

Product

Resources

About